Hong Zhu1,2, Zhenquan Jia3, Hara Misra1,2, Y Robert Li1,2,4. 1. Department of Pharmacology, Edward Via College of Osteopathic Medicine, Virginia Tech Corporate Research Center. 2. Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University. 3. Department of Biology, University of North Carolina at Greensboro, Greensboro, North Carolina, USA. 4. Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, Virginia.
Abstract
Alcoholic liver disease (ALD) is a major cause of morbidity and mortality in the United States and Europe. The spectrum of ALD ranges from fatty liver to alcoholic hepatitis and cirrhosis, which may eventually lead to hepatocellular carcinoma. In developed countries as well as developing nations, ALD is a major cause of end-stage liver disease that requires liver transplantation. The most effective therapy for ALD is alcohol abstinence; however, for individuals with severe ALD and those in whom alcohol abstinence is not achievable, targeted therapies are absolutely necessary. In this context, advances of our understanding of the pathophysiology of ALD over the past two decades have contributed to the development of therapeutic modalities (e.g., pentoxifylline and corticosteroids) for the disease although the efficacy of the available treatments remains limited. This article is intended to succinctly review the recent experimental and clinical findings of the involvement of oxidative stress and redox signaling in the pathophysiology of ALD and the development of mechanistically based antioxidant modalities targeting oxidative stress and redox signaling mechanisms. The biochemical and cellular sources of reactive oxygen and nitrogen species (ROS/RNS) and dysregulated redox signaling pathways associated with alcohol consumption are particularly discussed to provide insight into the molecular basis of hepatic cell dysfunction and destruction as well as tissue remodeling underlying ALD.
Alcoholic liver disease (ALD) is a major cause of morbidity and mortality in the United States and Europe. The spectrum of ALD ranges from fatty liver to alcoholic hepatitis and cirrhosis, which may eventually lead to hepatocellular carcinoma. In developed countries as well as developing nations, ALD is a major cause of end-stage liver disease that requires liver transplantation. The most effective therapy for ALD is alcohol abstinence; however, for individuals with severe ALD and those in whom alcohol abstinence is not achievable, targeted therapies are absolutely necessary. In this context, advances of our understanding of the pathophysiology of ALD over the past two decades have contributed to the development of therapeutic modalities (e.g., pentoxifylline and corticosteroids) for the disease although the efficacy of the available treatments remains limited. This article is intended to succinctly review the recent experimental and clinical findings of the involvement of oxidative stress and redox signaling in the pathophysiology of ALD and the development of mechanistically based antioxidant modalities targeting oxidative stress and redox signaling mechanisms. The biochemical and cellular sources of reactive oxygen and nitrogen species (ROS/RNS) and dysregulated redox signaling pathways associated with alcohol consumption are particularly discussed to provide insight into the molecular basis of hepatic cell dysfunction and destruction as well as tissue remodeling underlying ALD.
Authors: Thomas H Frazier; Abigail M Stocker; Nicole A Kershner; Luis S Marsano; Craig J McClain Journal: Therap Adv Gastroenterol Date: 2011-01 Impact factor: 4.409
Authors: Jessica I Cohen; Sanjoy Roychowdhury; Patricia M DiBello; Donald W Jacobsen; Laura E Nagy Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: Hong Zhu; Zhenquan Jia; Bhaba R Misra; Li Zhang; Zhuoxiao Cao; Masayuki Yamamoto; Michael A Trush; Hara P Misra; Yunbo Li Journal: Cardiovasc Toxicol Date: 2008-05-08 Impact factor: 3.231
Authors: Joanne M Ajmo; Xiaomei Liang; Christopher Q Rogers; Brandi Pennock; Min You Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-08-28 Impact factor: 4.052
Authors: Michael J Duryee; Monte S Willis; Courtney S Schaffert; Roger D Reidelberger; Anand Dusad; Daniel R Anderson; Lynell W Klassen; Geoffrey M Thiele Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-11-27 Impact factor: 4.052
Authors: Adele Stewart; Biswanath Maity; Simon P Anderegg; Chantal Allamargot; Jianqi Yang; Rory A Fisher Journal: Proc Natl Acad Sci U S A Date: 2015-02-02 Impact factor: 11.205
Authors: Letiția Adela Maria Streba; Cristin Constantin Vere; Costin Teodor Streba; Marius Eugen Ciurea Journal: World J Gastroenterol Date: 2014-07-07 Impact factor: 5.742